Please login to the form below

lenalidomide

This page shows the latest lenalidomide news and features for those working in and with pharma, biotech and healthcare.

Janssen scores another expansion for new Darzalex combination in the US

It also has an approval for another combination regimen made up of Darzalex, Celgene’s Revlimid (lenalidomide) and dexamethasone, for the treatment of newly diagnosed multiple myeloma patients who are ineligible

Latest news

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

BMS’ biggest seller was its multiple myeloma therapy Revlimid (lenalidomide), which it added to its portfolio following the Celgene acquisition.
In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

The anti-CD38 antibody is an option for patients who have been treated with at least two prior therapies, including BMS’ Revlimid (lenalidomide) and a proteasome inhibitor such as Takeda’s
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed
FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

Sarclisa will now be available for patients with relapsed or refractor multiple myeloma who have received at least two prior therapies, including Celgene’s Revlimid (lenalidomide) and a proteasome inhibitor.
Celgene’s Revlimid scores NICE approval in follicular lymphoma

Lenalidomide is a new type of targeted cancer therapy for people with previously treated follicular lymphoma. ... Lenalidomide fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease

More from news
Approximately 14 fully matching, plus 104 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of new Celgene brands like blood cancer therapies Revlimid (lenalidomide) and Pomalyst (pomalidomide)
European biotech: a new generation of leaders emerges

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
Building a business that is lean and specialised

drug Revlimid (lenalidomide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...